Skip to content

Conversion of ocular myasthenia gravis after treatment with Chinese medicine: A multicenter retrospective study

Conversion of ocular myasthenia gravis after treatment with Chinese medicine: A multicenter retrospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000797
Enrollment
Unknown
Registered
2024-12-11
Start date
2022-04-26
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular myasthenia gravis

Interventions

Western medicine group (using only Western medicine treatment):Western medicine treatment
Combined group (utilizing both traditional Chinese medicine and Western medicine treatments):Combination therapy of traditional Chinese and Western medicine

Sponsors

the first affiliated hospital of Zhejiang Chinese Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) The first onset meets the diagnostic criteria for ocular myasthenia gravis classification; 2) Traditional Chinese medicine has been involved in treatment for more than 3 months; 3) The admission information is complete the description of the patient's condition is detailed the medical records are complete and there are no obvious missing items. 4) Patients with ocular myasthenia gravis have a disease course of more than 2 years. 5) Age over 18 years old Only those who meet the above 5 criteria can be included in this study. OMG diagnosis is verified again by at least two attending physicians or higher-level physicians based on typical clinical phenotypes and laboratory test results.

Exclusion criteria

Exclusion criteria: 1)1) Combine patients with other neuromuscular diseases or peripheral neuropathy; 2) Patients with severe cardiovascular hepatic renal and hematopoietic system diseases chronic severe infections and mental illnesses. 3) Pregnant or lactating women patients. Note: Anyone who meets any of the above criteria will be excluded

Design outcomes

Primary

MeasureTime frame
Conversion of ocular myasthenia gravis;

Countries

China

Contacts

Public ContactZhengxiang Zhang

The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine

jxzhangzx@163.com+86 151 5819 6962

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026